Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Merck KGaA May Withdraw Research from Portugal over Debt-Report

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/09/2012 | 08:28am CET

German chemical company Merck KGaA (>> Merck KGaA) may withdraw future investments for research projects in Portugal worth tens of millions of euros unless the government hospitals stick to the agreed-upon debt repayments, German daily newspaper Financial Times Deutschland reports Monday.

Merck Portugal's manager Fritz Sacher told the paper the company's research projects are long-term and require mutual trust as a basis. "The Portuguese government's lacking payment habits undermine this trust," he is quoted as saying.

Portuguese government hospitals owe the pharmaceutical industry a total of more than 1.5 billion euros ($1.84 billion) and companies have to wait nearly 550 days on average until invoices are paid, FTD reports.

Some companies, including Roche Holding AG (ROG.VX), have already halted the sale of medications on credit to highly indebted countries like Portugal, Greece, Spain and Italy until outstanding debts are paid, the paper notes, but for many companies such drastic steps are difficult as they carry responsibility for people's wellbeing.

Withdrawing research projects is a way of putting pressure on the government, as Portugal is an attractive location for research investments, FTD says. "The conditions for certain research and human studies are as good as in the U.S., but it's significantly more cost-effective in Portugal," Sacher told the paper.

Newspaper website: http://www.ftd.de

Write to the Frankfurt Bureau at djnews.frankfurt@dowjones.com

Stocks mentioned in the article : Merck KGaA
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK KGAA
02/24 MERCK : Researchers from Merck KGaA Detail Findings in Robotics [Development of ..
02/24 MERCK : Receives Positive CHMP Opinion for New Pergoveris® Fertility Pen
02/16 MERCK : North American Businesses of Merck KGaA, Darmstadt, Germany Certified as..
02/16 MERCK : New Hypertension Findings from Merck KGaA Described [Management of Hyper..
02/15 MERCK : to Supply Single-Use Systems to WuXi Biologics for Non-GMP Pilot Plant i..
02/09 Verastem Announces Dosing of First Patient in Combination Trial of Defactinib..
02/09 MERCK : North American Businesses of Merck KGaA, Darmstadt, Germany Certified as..
02/09 MERCK : Cladribine Tablets Significantly Reduced Brain Atrophy in Patients with ..
02/07 MERCK : Jaffrey biochemical company to pay fine by EPA after alleged water pollu..
02/07 MERCK : Millipore settles lawsuit with EPA
More news
Sector news : Specialty & Advanced Pharmaceuticals
09:38pDJJOHNSON & JOHNSON : Prescription Unit List Prices Rose 8.5% Last Year
06:13p FTSE ends higher on some positive earnings, insurers slip
08:06aDJSANOFI : Lonza to Invest CHF290 Million in New Plant in Switzerland
02/24DJSHIRE : Files 8K - Other Events
02/24DJASTRAZENECA : Hyperkalaemia Drug Clears Scientific Hurdle for European Approval
More sector news : Specialty & Advanced Pharmaceuticals
News from SeekingAlpha
07:38a Roche's Renal Success Spells Danger For All-Comer Studies
02/03 Pfizer May Be Another IBM
01/23 Merck KGaA teams up with Domain Therapeutics in immuno-oncology
01/18 Astra's Mystic Mystery And Other Surprises In Store
01/12 Vertex And German Merck Find Their Perfect Fit
Advertisement
Financials (€)
Sales 2016 15 060 M
EBIT 2016 3 447 M
Net income 2016 1 795 M
Debt 2016 11 019 M
Yield 2016 1,19%
P/E ratio 2016 24,34
P/E ratio 2017 23,23
EV / Sales 2016 1,62x
EV / Sales 2017 1,44x
Capitalization 13 338 M
More Financials
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 109 €
Spread / Average Target 5,7%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stefan Oschmann Chief Executive Officer
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA4.08%14 073
ABBVIE INC-0.85%98 967
KYOWA HAKKO KIRIN CO L..3.65%8 659
JAZZ PHARMACEUTICALS P..24.84%8 152
MALLINCKRODT PLC7.15%5 589
ZHANGZHOU PIENTZEHUANG..3.69%4 173
More Results